Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Esperion Therapeutics Inc ESPR

Healthcare
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.


NDAQ:ESPR - Post by User

Esperion Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(89)
•••
Post by whytestockson Jun 01, 2023 11:45pm
97 Views
Post# 35476266

Esperion Announces Submission of Supplemental New Drug Appli

Esperion Announces Submission of Supplemental New Drug Appli
JUST IN: $ESPR Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL&#xAE; (bempedoic acid) Tablet and NEXLIZET&#xAE; (bempedoic acid and ezetimibe) Tablet&#x2013;&#xA0;Submitted four efficacy supplements seeking inclusion of CV risk reduction and expansion of LDL-C lowering &#x2013; &#x2013;&#xA0;Anticipated approvals in U.S. in the first half of 2024 &#x2013; ANN ARBOR, Mich., June 01, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ...ESPR - Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL&#xAE; (bempedoic acid) Tablet and NEXLIZET&#xAE; (bempedoic acid and ezetimibe) Tablet

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities